Ibogamine Purification via DCVC for Scalable Pharmaceutical Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in the preparation of ibogamine lies in obtaining a sufficiently pure product suitable for pharmaceutical applications in good yields, while ensuring scalability for industrial production.
Innovation Solution
A three-step process involving demethylation of ibogaine using a dealkylating agent, modification with a triflating agent, and elimination of the O-triflate group using a reducing agent, followed by purification through Dry Column Vacuum Chromatography (DCVC) and crystallization of free base ibogamine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to prepare ibogamine, then the product can be obtained, but the purity is insufficient for pharmaceutical applications
Solution Approach 1:
The synthesis is divided into distinct sequential steps: demethylation of ibogaine to noribogaine, conversion to the triflate derivative, and final reduction to ibogamine. Each step is optimized independently to ensure high purity while maintaining scalability for industrial production.
2Productivity
If conventional methods are used to prepare ibogamine, then the product can be obtained, but the yield is not sufficient for industrial applications
Solution Approach 1:
The methodology optimizes reaction parameters including solvent selection (e.g., using THF for demethylation), reagent ratios, temperature control, and reaction time to achieve both high yields and high purity. The triflation step uses specific conditions to maximize conversion while minimizing side products.
3Ease of manufacture
If the preparation process is simplified, then scalability is improved, but the purity and yield decrease
Solution Approach 1:
The triflate derivative serves as a key intermediary compound that enables efficient transformation from noribogaine to ibogamine. This intermediate step, while adding a reaction stage, actually simplifies the overall process by providing a stable, easily purified compound that can be handled at scale.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves ibogamine with high purity and yield, suitable for pharmaceutical applications, and is scalable for industrial production.
Implementation Method 1
eliminating the O-triflate group from 12-TfO-ibogamine by reacting 12-TfO-ibogamine provided in step ii) with a reducing agent to provide ibogamine, wherein the reducing agent comprises: a palladium catalyst, and a phosphine ligand
Implementation Method 2
method for purifying ibogamine and ibogamine-type compounds, by DCVC
Implementation Method 3
method for crystallizing ibogamine, in particular free base ibogamine
Data Source
AI summary
The present disclosure is directed to a method for the preparation of ibogamine, in particular from ibogaine; to a method for purifying ibogamine and ibogamine-type compounds by Dry Column Vacuum Chromatography (DCVC); and to a method for crystallizing ibogamine, in particular free base ibogamine.